Median Survival for Stage 4 ALK-Positive NSCLC Nearly 7 Years
MONDAY, Jan. 14, 2019 -- The median overall survival (OS) from diagnosis for patients with stage IV anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) is 6.8 years, according to a study published online Dec. 29 in the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer | Pharmaceuticals | Study